Bazedoxifene, a selective estrogen receptor modulator is thought to have effective anti-tumoral properties for pancreatic cancer via IL-6 pathway (GP130/STAT3) inhibition.
The objective is to measure IL-6 (GP130/STAT3)-pathway modification on metastasis biopsy of patients with metastatic pancreatic adenocarcinoma before and after treatment with bazedoxifene in addition to chemotherapy.
This study is a single-center, prospective, nonrandomized trial.

开始日期2022-02-01

申办/合作机构

Hopital Fribourgeois

EUCTR2021-005247-78-CZ

/ Not yet recruiting临床2期

A 2-Part, Open-label, Non-randomized (Part A) and Randomized, Double-blinded, Placebo-controlled (Part B) multicentric, international study with adaptive design to evaluate safety and tolerability of bazedoxifene, concentrated solution for nebulization (BAZE-X1) in addition to Standard of Care in hospitalized COVID-19 patients suffering from moderate to severe Pneumonia.

开始日期2022-01-19

申办/合作机构-

NCT04821141

/ Recruiting临床2期IIT

Randomized IIB Study of the Effect of Bazedoxifene Plus Conjugated Estrogens on Breast Imaging and Tissue Biomarkers in Peri or Post-Menopausal Women at Increased Risk for Development of Breast Cancer

Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine needle aspiration (RPFNA). Change in biomarkers will be compared between groups.

开始日期2021-12-14

申办/合作机构

University of Kansas

[+1]

100 项与醋酸巴多昔芬相关的临床结果

登录后查看更多信息

100 项与醋酸巴多昔芬相关的转化医学

登录后查看更多信息

100 项与醋酸巴多昔芬相关的专利（医药）

登录后查看更多信息

607

项与醋酸巴多昔芬相关的文献（医药）

2024-12-31·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells

Article

作者: Hou, Wenbin ; Li, Yiliang ; Chen, Leyuan ; Ren, Zhonghao ; Zhang, Yunze

Specifically inducing the degradation of acidic nucleoplasmic DNA-binding protein 1 (And1) is a promising antitumor strategy. Our previous study identified Bazedoxifene (BZA) and CH3 as specific And1 degraders and validated their activity in reversing radiotherapy resistance in vitro and in vivo. However, unelucidated structure-activity relationships and moderate activity have limited their application. In this study, 27 novel CH3 derivatives were designed and synthesised based on the cavity topology of the WD40 domain of And1. Among them, A15 with a "V" conformation significantly induced And1 degradation in NSCLC cells. In addition, this study demonstrated a potential synthetic lethal effect of And1 degraders and PARP1 inhibitors. 1 µM of Olaparib in combination with 5 µM of A15 significantly inhibited the proliferation of A549 and H460 cells. Overall, these compounds are valuable tools for elucidating And1 biology, and their special spatial conformation make them promising candidates for future optimisation studies.

2024-12-01·BIOORGANIC CHEMISTRY

Structurally diverse design and synthesis of novel 2-phenylindole amide derivatives with anti-canine breast cancer activity

Article

作者: Yin, Lizi ; Li, Haohuan ; Liang, Xiaoxia ; Wang, Han ; Wang, Zhenyu ; Xu, Funeng ; Tang, Huaqiao ; Wu, Pan ; Dong, Zhenghua ; He, Changliang ; Niu, Yan

Breast cancer stands as the cancer with the highest incidence and mortality rates among women globally, in which triple-negative breast cancer has been ranked as the most difficult one. Bazedoxifene (BZA), a third-generation selective estrogen receptor modulator (SERM), has been exhibited notable inhibitory effect on both hormone-dependent breast cancer cells and triple-negative breast cancer cells, but showing very low in vivo effeacy. In order to obtain more effective antitumor derivatives than BZA, we have employed a structurally diverse design and synthesis of 57 novel 2-phenylindole amides for detecting their cytotoxities against triple-negative mammary cancer cell line, CMT-7364. Among them, 21 compounds demonstrated significant inhibitory activity against CMT-7364 cells (IC₅₀ < 20 μM). Notably, compound 49 stood out, displaying both similar tumor cell inhibition (20 % reduce in IC₅₀ value) and higher selectivity (4.6 times higher in SI value), compared to Bazedoxifene. Additionally, compound 49 exhibited desirable antitumor effects in a CMT-7364 cell-derived mouse in vivo model, achieving the best inhibition rate of 43.1 % and establishing strong molecular bonding with GP130. Our findings are also supported by comprehensive SAR and 3D-QSAR analyses. Furthermore, the best potent compound 49 was determined to block the cell cycle of canine breast cancer cells in the G0G1 phase in a time-dependent manner, by inducing apoptosis and autophagy. In conclusion, this work presents a valuable lead compound as a potential GP130 inhibitor against triple-negative breast cancer cell lines, laying the foundation for further antitumor drug development.

2024-11-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Biochemical and biophysical characterization of Leishmania donovani citrate synthase

Article

作者: Ranjan, Preeti ; Dubey, Vikash Kumar ; Sarma, Manash

Citrate synthase is a crucial enzyme in the TCA cycle and represents a potential therapeutic target. However, knowledge about this enzyme in Leishmania parasites remains limited. In this study, we have successfully cloned, expressed, and purified citrate synthase from Leishmania donovani (LdCS) using a bacterial system, and characterized it through various biophysical and biochemical methods. Circular dichroism analysis at physiological pH indicates that LdCS is properly folded. Further investigation into its tertiary structure using a quencher reveals that most tryptophan residues are located within the protein's hydrophobic core. Biochemical assays show that the recombinant enzyme is catalytically active, with optimal activity at pH 7.0. Kinetic studies provided parameters such as Km and Vmax. Enzyme inhibition assays revealed that LdCS activity is competitively inhibited by FDA-approved compounds-Abemaciclib, Bazedoxifene, Vorapaxar, and Imatinib-with Ki values ranging from 2 to 3 μM, demonstrating significant binding affinity. This research paves the way for exploring LdCS as a potential drug target for treating leishmaniasis.

项与醋酸巴多昔芬相关的新闻（医药）

2024-09-10

·drugs

Review Weighs Treatments for Genitourinary Symptoms of Menopause

TUESDAY, Sept. 10, 2024 -- Vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, and vaginal moisturizers may be beneficial for some genitourinary symptoms of menopause (GSM), according to a review published online Sept. 10 in the Annals of Internal Medicine . Elisheva R. Danan, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM in a systematic review of randomized controlled trials (RCTs). A total of 46 RCTs assessing vaginal estrogen, nonestrogen hormones, vaginal moisturizers, or multiple interventions were identified from 11,993 citations. The researchers found that vaginal estrogen may improve vulvovaginal dryness, dyspareunia , the most bothersome symptom, and treatment satisfaction compared with placebo or no treatment. Vaginal DHEA may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms compared with placebo; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and dryness may also be improved by vaginal moisturizers (all low certainty of evidence [COE]). No benefit or uncertain effects (low and very low COE, respectively) may be provided by vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene. Reporting was limited by studies of short duration that were insufficiently powered to assess infrequent serious harms. "Future studies would be strengthened by standard definitions of symptoms and uniform diagnostic criteria for GSM, a common set of validated outcome measures and reporting standards, and attention to clinically relevant patient populations and intervention comparisons," the authors write.

临床结果

2023-09-12

·PRNewswire

Menopause Market to Grow Rapidly at a CAGR of 1.2% by 2032, Predicts DelveInsight

The menopause market is anticipated to surge significantly in the coming years due to the emergence of new products in the pipeline. In addition, persistently rising cases of menopause in the forecast period will help increase the menopause treatment market. LAS VEGAS, Sept. 12, 2023 /PRNewswire/ -- DelveInsight's Menopause Market Insights report includes a comprehensive understanding of current treatment practices, menopause emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Menopause Market Report As per DelveInsight analysis, the menopause market size in the 7MM was approximately USD 11 billion in 2022. According to the assessment done by DelveInsight, the total number of women in menopause in the 7MM comprised approximately 100 million cases in 2022 and are projected to increase during the forecast period. Leading menopause companies such as Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others are developing novel menopause drugs that can be available in the menopause market in the coming years. The promising menopause therapies in the pipeline include Transdermal Estradiol Cream (VML-0203), DONESTA (E4, Estetrol), Elinzanetant (BAY3427080), MT-8554 (Elismetrep), MNGX-100 (Filgrastim/G-CSF), Q-122 (MSX-122), FP-101, and others. Discover which therapies are expected to grab the major menopause market share @ Menopause Market Report Menopause Overview Menopause is a natural biological process that marks the end of a woman's reproductive years. It usually occurs between the ages of 45 and 55, with an average age of around 51. This phase is characterized by a decline in the production of hormones like estrogen and progesterone, leading to the cessation of menstruation and fertility. The primary cause of menopause is the aging of the ovaries, which results in a reduced number of eggs and a decline in hormone production. However, certain medical procedures like hysterectomy, chemotherapy, and radiation therapy can induce menopause prematurely. Menopause brings about a range of symptoms that can vary widely from woman to woman. Common menopause symptoms include hot flashes, night sweats, mood swings, irritability, fatigue, vaginal dryness, and sleep disturbances. These symptoms occur due to the hormonal fluctuations that take place during the transition to menopause. Diagnosing menopause is often based on a woman's age, medical history, and symptoms. A key factor is the absence of menstruation for 12 consecutive months, signaling the end of the reproductive period. In some cases, healthcare providers may recommend blood tests to measure hormone levels, such as follicle-stimulating hormone (FSH) and estrogen, to confirm the onset of menopause. Menopause Epidemiology Segmentation DelveInsight estimates that there were approximately 100 million total women in menopause in the 7MM in 2022. For the age-specific analysis, the number of cases of menopause were distributed across various age groups, such as <40 years, 40–50 years, 51–60 years, and 61–65 years, in the 7MM. As per the analysis, the highest number of cases were estimated in the age-group 51-60 years and the lowest in <40 years with 64 million and 3.4 million cases, respectively in 2022. The menopause market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Number of Women in Menopause Stage-Specific Distribution of Women in Menopause Age-Specific Distribution of Women in Menopause Number of Women in Menopause with Vasomotor Symptoms Number of Women in Menopause with Moderate-to-Severe Vasomotor Symptoms Menopause Treatment Market The North American Menopause Society (NAMS) suggests waiting until the hot flashes become troublesome to the woman before seeking treatment. The intensity of symptoms, an assessment of treatment-related risks, and the woman's views towards menopause and drugs should all be considered before starting treatment. Duavee (bazedoxifene acetate/conjugated estrogens) is the first and only medicine that combines CE with an estrogen agonist/antagonist, commonly known as a selective estrogen receptor modulator (SERM), for the treatment of menopausal VMS. Duavee employs bazedoxifene rather than progestin to help protect the uterine lining from hyperplasia that may occur as a result of estrogen-only treatment. Many women use non-prescription therapies to address disorders such as hot flashes, such as isoflavones, black cohosh, and progesterone-containing hormone lotions. The clinical evidence for the efficacy and long-term safety of these therapies is insufficient. Furthermore, most over-the-counter medications for hot flashes are classified as nutritional supplements and, as such, are not regulated by the US Food and Drug Administration. Prescription medications for various purposes that have demonstrated some benefit in alleviating hot flashes are available for women who have hot flashes but cannot undergo hormone therapy. Certain prescription antidepressants may reduce hot flashes in women, including those with a history of breast cancer. Others include gabapentin, clonidine, and methyldopa. The NAMS recommends that women who need relief from mild menopause-related hot flashes first consider lifestyle changes such as manipulating the environment to keep the core body temperature cool, getting regular exercise, quitting smoking, and using relaxation techniques such as paced respiration. To know more about menopause treatment, visit @ Menopause Treatment Drugs Key Menopause Therapies and Companies Transdermal Estradiol Cream (VML-0203): Viramal Limited/Simbec Research DONESTA (E4, Estetrol): Estetra/Mithra Pharmaceuticals Elinzanetant (BAY3427080): Bayer|Nerre Therapeutics Ltd. MT-8554 (Elismetrep): Mitsubishi Tanabe Pharma America Inc. MNGX-100 (Filgrastim/G-CSF): MenoGeniX Q-122 (MSX-122): QUE Oncology FP-101: Fervent Pharmaceuticals Learn more about the FDA-approved drugs for menopause @ Drugs for Menopause Treatment Menopause Market Dynamics The menopause market dynamics are undergoing significant shifts as societal awareness of women's health and well-being continues to grow. With an aging population and increasing focus on women's empowerment, there's a heightened demand for innovative products and services addressing the physical and emotional challenges associated with menopause. This has spurred a surge in research and development, leading to the creation of a diverse range of hormone replacement therapies, herbal supplements, lifestyle apps, and personalized health plans. As more women seek effective and holistic solutions, companies are embracing a more consumer-centric approach, tailoring their offerings to individual needs and preferences. Additionally, discussions around menopause are becoming less taboo, allowing for open dialogue and information-sharing, further shaping the menopause market dynamics by fostering a supportive ecosystem for women navigating this life stage. However, despite the potential for growth, this menopause market is not without its barriers. Stringent regulatory processes for hormonal treatments and supplements, coupled with concerns about product safety and efficacy, pose challenges for menopause market entrants. Additionally, cultural stigmas and misinformation surrounding menopause still exist in certain societies, inhibiting open discussions and the adoption of new solutions. Economic disparities and limited access to healthcare further compound these issues, preventing equal menopause market penetration. Overcoming these barriers requires a multi-faceted approach, involving education, regulatory reforms, and inclusive product development, to truly tap into the menopause market's potential. Scope of the Menopause Market Report Therapeutic Assessment: Menopause current marketed and emerging therapies Menopause Market Dynamics: Attribute Analysis of Emerging Menopause Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's Views, Analyst's Views, Menopause Market Access and Reimbursement Discover more about menopause drugs in development @ Menopause Clinical Trials Table of Contents Related Reports Hot Flashes Pipeline Hot Flashes Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, among others. Hot Flashes Market Hot Flashes Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, among others. Menopause Global Market Menopause Market Insights, Competitive Landscape, and Market Forecast – 2028 report deliver an in-depth understanding of the disease, market trends, market drivers, market barriers, and key menopause companies including ISIDEN, Novapharm, Arkopharma, Pileje, Thermamex, ÉLERTÉ Laboratories, Serelys Pharma, Besins Healthcare, Bayer, ITALFARMACO S.p.A, Pfizer Inc, Mylan NV, Teva Pharmaceuticals, TherapeuticsMD, Inc, Novo Nordisk, Novartis, Millicent Pharma, PADAGIS LLC, Vertical Pharmaceuticals LLC, Amgen, among others. Vasomotor Symptoms of Menopause Pipeline Vasomotor Symptoms of Menopause Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key vasomotor symptoms of menopause companies, including Mithra Pharmaceuticals, Acer Therapeutics, QUE Oncology, Bayer, Endoceutics, Astellas Pharma, Mitsubishi Tanabe Pharma, MenoGenix, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

2022-06-30

·药明康德

治疗不足现象突出！《自然》子刊综述：女性进入这个关键年龄段，如何合理应用激素治疗?

▎药明康德内容团队编辑绝大多数经历绝经期的女性都会面临令人烦恼的雌激素缺乏症状，绝经期雌激素水平的下降会引起女性身体无症状的生物学变化，并且增加非传染性疾病，如心血管疾病、2型糖尿病、骨质疏松、特定类型癌症以及抑郁症的发病风险。值得一提的是，提早绝经的女性这些疾病发生的风险更高。近日，《自然》子刊 Nature Reviews Endocrinology 发表重磅综述，围绕绝经的短期和远期影响、绝经相关症状治疗适应症以及绝经潜在治疗药物进行详细阐述。论文强调，对于有症状的绝经期女性，雌激素仍然是最有效的治疗方法。绝经激素疗法（MHT）不仅可以预防骨质流失以及骨折，如果在绝经期早期开始使用，还可用于预防心脏代谢疾病的发生。截图来源： Nature Reviews Endocrinology 绝经的短期和远期影响女性一生中需要经历很多个生理阶段，其中绝经期是女性从生育年龄过渡到老年的阶段。绝经后女性卵巢的功能基本消失，这一过程可能自然发生（自然绝经）或基于医源性因素发生（继发性闭经）。目前在全球范围内，女性自然绝经的平均年龄为48.8岁，不同地区女性自然绝经年龄差异较小。女性绝经年龄对晚年健康具有重要影响。提早绝经与乳腺癌的发病风险降低有关，但是会增加卵巢早衰相关骨质疏松、心血管疾病和过早死亡的风险。绝经雌激素水平的下降会诱导衰弱性症状的产生，如血管舒缩症状（如潮热、盗汗）、焦虑、抑郁、泌尿生殖道萎缩、性功能障碍。此外，绝经后雌激素的缺乏也可能带来长期不良反应，其中最值得关注的包括骨质流失（骨折风险增加）、中心性（腹型）肥胖（增加心血管疾病发病风险）、2型糖尿病（T2DM）以及部分类型癌症的发病风险增加。目前最常报告的绝经期症状包括血管舒缩症状、睡眠障碍、情绪变化、关节痛、肌痛、泌尿生殖道萎缩、认知功能改变和体重增加。论文强调，绝大多数女性在45岁至55岁之间绝经，其中高达75%会出现雌激素缺乏相关症状。尽管目前临床上拥有安全的激素与非激素治疗手段，但是绝大多数伴有绝经症状的女性并未接受有效的、基于充足证据的获批治疗方法。绝经人群需要接受治疗的指征论文强调，雌激素水平下降将导致全身脂肪组织的增加和重新分布（内脏脂肪的比例增高），从而提高绝经人群心血管疾病、2型糖尿病、乳腺癌、子宫癌和结直肠癌的发病风险。由于绝经相关主要症状以及后遗症主要由于卵巢雌激素分泌减少所致，因此，基于雌激素、雌激素样化合物的绝经激素治疗（MHT）有望改善绝经期症状，并同时预防绝经期相关骨质流失、心脏代谢不良变化。 ▲雌激素水平变化对心脏代谢影响的可能途径（图片来源：参考资料[1]）绝经激素治疗最初的适应症包括绝经期症状的治疗以及绝经后女性（具有较高骨折风险）骨质疏松的预防。目前绝经激素治疗的适应症主要为绝经期血管舒缩症状。论文强调，女性绝经症状受到个人健康、社会心理、经济环境等多方面因素的影响，因此需考虑配合其他手段进行综合护理，如优化生活方式（如提高膳食营养、体能锻炼水平，减少饮酒和戒烟）、治疗慢性疾病相关的风险因素。绝经人群的治疗选择论文强调，绝经激素治疗（如使用药物替勃龙）是目前绝经相关症状最有效的治疗手段。在骨密度正常、骨量减少和骨质疏松的女性中，研究证实绝经激素治疗可显著降低受试者髋关节、椎体和其他骨质疏松相关骨折的风险。此外，对于常见的绝经相关泌尿生殖道萎缩，激素治疗结合非激素治疗手段也可为这部分人群带来积极获益。目前获批的绝经人群全身性激素治疗药物包括：雌激素类：结合型孕马雌激素（CEE）、微粉化17-β雌二醇、戊酸雌二醇、雌酮硫酸酯哌嗪、17-β雌二醇经皮吸收制剂、皮下埋植雌二醇、雌二醇凝胶、雌二醇半水合物凝胶；孕激素类：微粉化黄体酮、地屈孕酮、屈螺酮、醋酸炔诺酮、醋酸甲羟孕酮、左炔诺孕酮宫内节育系统；其他类型：替勃龙、共轭雌激素/巴多昔芬。对于不同类型的绝经人群，绝经激素治疗方案不同，具体而言对于接受子宫切除术的女性，应仅以最低有效剂量处方雌激素；对于保留子宫的女性，考虑到长期使用单一雌激素疗法可能会增加子宫内膜增生的发生风险，因此推荐雌激素治疗需与孕激素联合使用。此外，绝经期症状的非激素干预措施包括生活方式和饮食调整、非激素类药物、行为和替代疗法。但是，目前尚缺乏令人信服的证据证实，运动、营养补充剂或富含植物雌激素的饮食可有效缓解绝经相关症状，如血管舒缩症状。不过，越来越多的临床试验和荟萃分析的证据显示，特定抗抑郁药，如文拉法辛、帕罗西汀等，或可有效缓解绝经期血管舒缩症状。论文也强调，认知行为治疗有助于减少血管舒缩症状带来的影响，并可能对绝经期人群睡眠和情绪有额外益处。相关阅读《柳叶刀》子刊：乳腺癌5年复发风险进一步降低约32%，芳香化酶抑制剂对绝经前患者同样有效！《柳叶刀》专题：影响女性1/3生命，这个关键时期要保护心脏代谢健康为什么女性更多得甲状腺疾病？ JAMA 详述女性一生中的生理变化影响参考资料 [1] Davis, S.R., Baber, R.J. Treating menopause — MHT and beyond. Nat Rev Endocrinol (2022). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41574-022-00685-4 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系。如有其他合作需求，请联系wuxi_media@wuxiapptec.com

合作

100 项与醋酸巴多昔芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	醋酸巴多昔芬	G03XC02	DB06401

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
绝经期后骨质疏松	欧盟	Pfizer Europe MA EEIG	2009-04-17
绝经期后骨质疏松	冰岛	Pfizer Europe MA EEIG	2009-04-17
绝经期后骨质疏松	列支敦士登	Pfizer Europe MA EEIG	2009-04-17
绝经期后骨质疏松	挪威	Pfizer Europe MA EEIG	2009-04-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
子宫内膜增生	临床3期	美国	Pfizer Inc.	2009-01-01
子宫内膜增生	临床3期	阿根廷	Pfizer Inc.	2009-01-01
子宫内膜增生	临床3期	澳大利亚	Pfizer Inc.	2009-01-01
子宫内膜增生	临床3期	智利	Pfizer Inc.	2009-01-01
子宫内膜增生	临床3期	哥伦比亚	Pfizer Inc.	2009-01-01
子宫内膜增生	临床3期	丹麦	Pfizer Inc.	2009-01-01
子宫内膜增生	临床3期	芬兰	Pfizer Inc.	2009-01-01
子宫内膜增生	临床3期	匈牙利	Pfizer Inc.	2009-01-01
子宫内膜增生	临床3期	墨西哥	Pfizer Inc.	2009-01-01
子宫内膜增生	临床3期	新西兰	Pfizer Inc.	2009-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2023	N/A	乳腺癌	21	Bazedoxifene 20 mg + Conjugated estrogen 0.45 mg	襯艱鹽糧顧淵製繭蓋蓋(憲網製觸艱淵鬱範夢壓) = 蓋願繭鏇築鹹構繭獵衊鬱壓網製繭糧遞壓鏇襯 (築範鬱願齋廠選顧衊鏇 )	-	2023-04-04
				bazedoxifene (Wait list control)	襯艱鹽糧顧淵製繭蓋蓋(憲網製觸艱淵鬱範夢壓) = 積壓觸憲齋遞蓋築獵網鬱壓網製繭糧遞壓鏇襯 (築範鬱願齋廠選顧衊鏇 )
NCT02448771 (Pubmed)	临床2期	HR阳性乳腺癌	36	Bazedoxifene plus Palbociclib	廠鏇簾糧選獵艱窪築鬱(蓋鹽顧衊餘醖窪鏇艱憲) = 窪糧鹽齋選構窪壓窪觸壓糧鏇廠鏇顧壓築蓋鑰 (廠憲範壓廠選遞衊窪糧 ) 更多	积极	2022-10-10
NCT02602704 (Pubmed \| Arthritis Res Ther)	临床4期	类风湿关节炎	114	Bazedoxifene + calcium and vitamin D	顧夢網鬱築醖願糧夢築(壓構衊製壓憲鏇觸餘憲) = 構遞鑰範廠築襯醖遞夢鬱襯壓餘襯鹽選鹹選鑰 (顧糧繭衊遞衊廠願網窪 )	-	2021-07-02
				Calcium and vitamin D only	顧夢網鬱築醖願糧夢築(壓構衊製壓憲鏇觸餘憲) = 蓋夢膚繭廠窪製夢壓糧鬱襯壓餘襯鹽選鹹選鑰 (顧糧繭衊遞衊廠願網窪, 0.0003 ~ 0.026)
NCT02448771 (CTgov)	临床1/2期	HR阳性乳腺癌 \| 转移性乳腺癌 \| 浸润性乳腺癌	36	Bazedoxifene+palbociclib	簾憲選築顧觸憲鬱壓選(襯齋餘製壓壓膚膚夢構) = 繭窪範顧網範觸獵夢鹽廠淵蓋鹹築艱願淵壓觸 (夢網衊廠膚鑰願窪艱簾, 窪壓齋艱膚糧獵餘願鹽 ~ 鏇憲鏇簾衊齋衊積壓簾) 更多	-	2021-07-01
PD1-05 (SABCS2019)	临床1/2期	HR阳性乳腺癌 ER+ \| HER2-	36	Bazedoxifene 40mg + Palbociclib 125mg	獵簾選繭鹹廠窪製構築(構艱遞艱鑰遞壓簾衊齋) = 鹹鹽製鹽壓網鹽鹹餘壓醖夢觸醖構淵窪窪餘醖 (餘遞鑰窪鏇鹹糧糧遞願, 23 ~ 49) 更多	积极	2019-02-15
SABCS2018	N/A	乳腺癌 ER+	-	Bazedoxifene	鹽鑰選糧襯餘構製築衊(壓窪膚繭選蓋鹽獵獵簾) = 網顧憲餘窪鑰範製構獵願製鏇鹽憲衊窪壓鑰夢 (艱築膚鑰醖淵網醖衊鬱 ) 更多	-	2018-02-15
				Letrozole	鹽鑰選糧襯餘構製築衊(壓窪膚繭選蓋鹽獵獵簾) = 襯簾顧鑰製鬱齋窪窪顧願製鏇鹽憲衊窪壓鑰夢 (艱築膚鑰醖淵網醖衊鬱 ) 更多
WCO_IOF_ESCEO2015	临床4期	绝经期后骨质疏松	24	Bazedoxifene 20 mg	襯艱齋觸繭觸鏇觸觸餘(壓膚鏇範觸壓選選鑰鬱) = 窪餘顧蓋壓糧壓襯糧製繭廠製衊顧醖襯獵壓製 (獵鹽選蓋範構鹹衊顧廠 )	-	2015-04-17
NCT00808132 (Selective estrogens, Menopause, And Response to Therapy-5, CTgov)	临床3期	子宫内膜增生 \| 绝经期后骨质疏松	1,886	Bazedoxifene (Bazedoxifene 20 mg / Conjugated Estrogens 0.45 mg)	觸鏇積餘艱艱鬱艱積齋(鏇壓鑰繭製廠襯獵網蓋) = 遞鹽觸繭壓齋鏇簾繭範憲齋網願製選襯廠鬱夢 (憲糧積鬱廠夢醖選夢艱, 繭膚選鑰選艱築餘壓鬱 ~ 鏇鬱窪窪鬱鑰獵觸醖膚) 更多	-	2013-12-20
				Bazedoxifene (Bazedoxifene 20 mg / Conjugated Estrogens 0.625 mg)	觸鏇積餘艱艱鬱艱積齋(鏇壓鑰繭製廠襯獵網蓋) = 構壓壓餘範襯鏇顧醖鏇憲齋網願製選襯廠鬱夢 (憲糧積鬱廠夢醖選夢艱, 鹽醖憲窪鏇鑰淵淵襯壓 ~ 觸製繭淵遞衊構築衊築) 更多
NCT00205777 (CTgov)	临床3期	骨质疏松症 \| 骨折	7,609	Bazedoxifene (Bazedoxifene 20 mg (Core+SE I))	窪網網窪憲憲構網齋憲(簾憲鹹鹹鹹積簾壓鏇顧) = 選鬱製蓋廠鬱製選鬱鬱壓餘廠選製夢夢選顧廠 (獵鬱醖膚壓壓繭憲築蓋, 齋選膚膚網遞網範觸積 ~ 蓋鹽積鑰夢餘繭選選鏇) 更多	-	2013-04-10
				Bazedoxifene (Bazedoxifene 40 mg (Core))	窪網網窪憲憲構網齋憲(簾憲鹹鹹鹹積簾壓鏇顧) = 積遞構網襯範衊網壓繭壓餘廠選製夢夢選顧廠 (獵鬱醖膚壓壓繭憲築蓋, 鏇積範鏇顧膚願衊遞築 ~ 願獵製繭選鑰膚獵鹽鬱) 更多
NCT00238745 (Pubmed \| J Bone Miner Res)	临床2期	绝经期后骨质疏松	429	Bazedoxifene 20 mg	鬱齋簾廠範築簾鹽鏇壓(醖網鑰夢網鹽獵鬱鑰鹹) = 壓艱窪醖艱醖觸膚顧構製製鹽選廠構遞艱襯醖 (網襯鹽醖簾繭繭願選膚 )	-	2011-03-01
				Bazedoxifene 40 mg	鬱齋簾廠範築簾鹽鏇壓(醖網鑰夢網鹽獵鬱鑰鹹) = 獵壓範鏇顧願膚簾鏇顧製製鹽選廠構遞艱襯醖 (網襯鹽醖簾繭繭願選膚 )